Photo from wikipedia
Evidence about the treatment of hospitalized type 2 diabetes patients with incretin‐based therapy has emerged in the past 15 years. Based on this evidence, dipeptidyl peptidase‐4 inhibitors should be considered… Click to show full abstract
Evidence about the treatment of hospitalized type 2 diabetes patients with incretin‐based therapy has emerged in the past 15 years. Based on this evidence, dipeptidyl peptidase‐4 inhibitors should be considered for hospitalized patients with type 2 diabetes and an algorithm for this is proposed. In relation to use of glucagon‐like peptide‐1 and glucagon‐like peptide‐1 receptor agonist, further research is required to help define their role in the inpatient setting.
Keywords:
patients type;
incretin based;
type diabetes;
based therapy;
hospitalized patients
Journal Title: Journal of Diabetes Investigation
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Diabetes Investigation
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!